Shots:

• AbbVie reported pooled analysis and long-term integrated analysis of the P-lll RESONATE-2 and ILLUMINATE study evaluating Imbruvica as 1L treatment of high-risk patients with CLL. The data is presented at ASH 2020
• Results from an integrated analysis of two clinical trials ~6.5 yrs. of long-term follow-up demonstrate similar PFS and ORR in patients with/ out high-risk genomic features
• A pooled analysis across four clinical trials with ~8yrs. of follow-up result (RESONATE-2- iLLUMINATE- E1912)- and PCYC-1122e study showed sustained- long-term efficacy with high 4-year PFS rates in high-risk CLL patients. Additionally- real-world data indicate low biomarker testing rates for these patients

 ­ Ref: PRNewswire | Image: abbvie